Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study.

Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Hepatol Res. 2019 Mar 8. doi: 10.1111/hepr.13328. [Epub ahead of print]

PMID:
30849206
2.

Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.

Ogawa E, Furusyo N, Azuma K, Nakamuta M, Nomura H, Dohmen K, Satoh T, Kawano A, Koyanagi T, Ooho A, Takahashi K, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Antiviral Res. 2018 Nov;159:143-152. doi: 10.1016/j.antiviral.2018.10.003. Epub 2018 Oct 6.

PMID:
30300717
3.

Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.

Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Aliment Pharmacol Ther. 2018 Jan;47(1):104-113. doi: 10.1111/apt.14380. Epub 2017 Oct 16.

PMID:
29035002
4.

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.

Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y; Japanese Genome-Wide Association Study Group for Viral Hepatitis.

Gastroenterology. 2017 May;152(6):1383-1394. doi: 10.1053/j.gastro.2017.01.041. Epub 2017 Feb 3.

5.

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.

Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Gastroenterol. 2017 Jul;52(7):845-854. doi: 10.1007/s00535-016-1290-1. Epub 2016 Dec 2.

PMID:
27913920
6.

Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.

Ogawa E, Furusyo N, Nomura H, Takahashi K, Higashi N, Kawano A, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Antiviral Res. 2016 Dec;136:37-44. doi: 10.1016/j.antiviral.2016.10.012. Epub 2016 Oct 24.

PMID:
27789224
7.

Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity.

Kubota N, Kubota T, Kajiwara E, Iwamura T, Kumagai H, Watanabe T, Inoue M, Takamoto I, Sasako T, Kumagai K, Kohjima M, Nakamuta M, Moroi M, Sugi K, Noda T, Terauchi Y, Ueki K, Kadowaki T.

Nat Commun. 2016 Oct 6;7:12977. doi: 10.1038/ncomms12977.

8.

Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study.

Sawamoto R, Nagano J, Kajiwara E, Sonoda J, Hiramoto T, Sudo N.

Biopsychosoc Med. 2016 Jul 29;10:24. doi: 10.1186/s13030-016-0075-3. eCollection 2016.

9.

Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.

Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study(KULDS) Group.

Hepatol Res. 2017 Mar;47(3):E120-E131. doi: 10.1111/hepr.12738. Epub 2016 Jun 10.

PMID:
27142311
10.

Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C.

Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J.

World J Hepatol. 2015 Nov 18;7(26):2688-95. doi: 10.4254/wjh.v7.i26.2688.

11.

Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C.

Ikezaki H, Nomura H, Furusyo N, Ogawa E, Kajiwara E, Takahashi K, Kawano A, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Hepatol Res. 2016 Mar;46(3):E174-80. doi: 10.1111/hepr.12555. Epub 2015 Sep 2.

PMID:
26189962
12.

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.

Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J.

J Gastroenterol Hepatol. 2015 Dec;30(12):1759-67. doi: 10.1111/jgh.13016.

PMID:
26095167
13.

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.

Ogawa E, Furusyo N, Dohmen K, Kajiwara E, Kawano A, Nomura H, Takahashi K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Viral Hepat. 2015 Dec;22(12):992-1001. doi: 10.1111/jvh.12427. Epub 2015 Jun 15.

PMID:
26075320
14.

Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection.

Kawano A, Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Dohmen K, Nomura H, Takahashi K, Satoh T, Azuma K, Tanabe Y, Shimoda S, Kotoh K, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Intern Med. 2015;54(6):567-72. doi: 10.2169/internalmedicine.54.3457.

15.

Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.

Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Gastroenterol Hepatol. 2015 Aug;30(8):1309-16. doi: 10.1111/jgh.12945.

PMID:
25777545
16.

Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.

Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619.

PMID:
24731162
17.

Infection of adult thymus with murine retrovirus induces virus-specific central tolerance that prevents functional memory CD8+ T cell differentiation.

Takamura S, Kajiwara E, Tsuji-Kawahara S, Masumoto T, Fujisawa M, Kato M, Chikaishi T, Kawasaki Y, Kinoshita S, Itoi M, Sakaguchi N, Miyazawa M.

PLoS Pathog. 2014 Mar 20;10(3):e1003937. doi: 10.1371/journal.ppat.1003937. eCollection 2014 Mar.

18.

Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.

Ogawa E, Furusyo N, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Nakamuta M, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

Antiviral Res. 2014 Apr;104:102-9. doi: 10.1016/j.antiviral.2014.01.004. Epub 2014 Jan 23.

PMID:
24462955
19.

Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes.

Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E.

J Gastroenterol. 2014 Nov;49(11):1504-13. doi: 10.1007/s00535-013-0921-z. Epub 2013 Dec 8.

PMID:
24317936
20.

TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass.

Takamoto I, Kubota N, Nakaya K, Kumagai K, Hashimoto S, Kubota T, Inoue M, Kajiwara E, Katsuyama H, Obata A, Sakurai Y, Iwamoto M, Kitamura T, Ueki K, Kadowaki T.

Diabetologia. 2014 Mar;57(3):542-53. doi: 10.1007/s00125-013-3131-6. Epub 2013 Dec 8.

PMID:
24317852

Supplemental Content

Loading ...
Support Center